anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE:To provide the new 16beta-lower alkoxy-3alpha,17,18-trihydroxyaphidicolan having an antitumor action. CONSTITUTION:A compound of the formula (R is lower alkyl). The compound is obtained by reacting 3alpha,18-dihydroxy-16beta,17-epoxyaphidicolan with a lower alcohol (e.g. methanol) in the presence of an acidic substance (e.g. p- toluenesulfonic acid) as a catalyst at 0-100 deg.C. For example, 3alpha,17,18- trihydroxy-16beta-methoxyaphidicolan is produced as follows: introducing a 3alpha,18- isopropylidenedioxy group into 3alpha,16beta,18-trihydroxy-17-p- toluenesulfonyloxyaphidicolan, hydrolyzing the reaction product, introducing a trityloxy group at the 17-position of the hydrolyzed product, reacting the product with methyl iodide, converting the 16beta-position into a methoxy group, and subsequently hydrolyzing the 3alpha,18-isopropylidenedioxy group and the 17- trityloxy group.
Concurrent administration of antigen-pulsed dendritic cells and activated T cells to a patient is disclosed. Such administration results in maturation of dendritic cells, which allows dendritic cells to enter the lymph system. Co-administration of antigen-pulsed dendritic cells and activated T cells induce bidirectional stimulation in each cell population. As a result, cytokine productions such as IFN-η and IL-12 are greatly enhanced, and a Th1 type of immunologic response specific against the antigens is induced. The methods therefore elicit an immune response in a patient, and find application in the treatment of cancer, immune diseases, and viral infections. Formulations comprising the dendritic cells and activated T cells of the present invention are also disclosed.
FIELD: medicine. SUBSTANCE: method involves three-stages aerosol therapy (7-8 treatments for course, by 5-7 ml per inhalation for 5-7 min every day). At the first stage for sanitation of upper respiratory tracts herb infusions are used (gum-tree, pansy); at the second stage aerosol therapy with 0.1-0.5% ethonium solution is carried out to stimulate immune competent cells. Inhalation with 0.05-0.5% lysozyme solution at the third stage ensures to reach substituting effect. Aerosol therapy using herb infusions improving function of ciliated epithelium (pot-marigold, matricary, major plantain) ensures to correct disturbance in mucociliary transport. Morbidity of children is decreased by 2.5 times. EFFECT: enhanced efficacy of method.
Therapeutic treatment as well as propylactic measures are provided by topical application of compositions containing an aryl 2-acetoxyethanoic acid to eradicate or prevent the development of axillary foul odor, foot malodor and other body odors, e.g. scalp, and skin, nail and follicular infections caused by microorganisms. The compositions are antimicrobial against several organisms that infect the skin and are specifically effective against P.  acnes. The compositions are therapeutically effective against folliculitis and perifolliculitis and are useful for other skin lesions, nail and mucosal infections such as impetigo, seborrheic dermatitis, erythrasma and thrichomycosis axillaris, associated with or caused by microorganisms. The therapeutic effect of the composition may be synergized or amplified by incorporating a cosmetic or dermatologic agent into the formulation for topical treatment of cosmetic and dermatologic indications. The compositions are also useful as preservatives in food products, cosmetic and pharmaceutical formulations, and industrial preparations.
Many problems may develop in patients on mechanical ventilation support in intensive care units. The most important of these is ventilator-associated pneumonia (VAP) caused by inadequate oral care in patients on mechanical ventilator support. The aim of the thesis is to examine the effect of chlorhexidine gluconate, sodium bicarbonate, ozonated water and hypochlorous acid solutions used in oral care in preventing ventilator-associated pneumonia in patients on mechanical ventilation support.

This research was planned as a randomized controlled experimental study. The sample of the study will consist of 105 intubated adult patients hospitalized in the Anesthesia and Reanimation Intensive Care Unit of the Republic of Turkey Ministry of Health Aydın Provincial Health Directorate Nazilli State Hospital. Patients will be divided into a total of 5 groups: 4 experimental and 1 control group. The groups to which 1% chlorhexidine gluconate, sodium bicarbonate, ozonated water and hypochlorous acid solutions are applied will constitute the experimental group, and the patients who receive oral care with 0.12% chlorhexidine gluconate, which is routinely applied in the clinic, will constitute the control group. Patients will be given oral care by the nurse with determined solutions (chlorhexidine gluconate, sodium bicarbonate, ozonated water and hypochlorous acid) 4 times a day according to the oral care protocol, and the oral mucosa of all patient groups will be evaluated every morning for 7 days. A deep tracheal aspirate sample will be taken and a chest x-ray will be taken on the first and seventh days after hospitalization of intubated patients. The development of VAP in patients will be evaluated with the clinical pulmonary infection score.
Part 3 daytime oral dose of JNJ-48816274 or placebo administered once daily for 7 consecutive days. Doses will be determined based on data from Part 1, and may increase sequentially (not to exceed 250 mg/day).
<P>PROBLEM TO BE SOLVED: To provide a detergent which can improve the detergency of strongly alkaline electrolytic water generated from an electrolytic water generator, and maintain the detergency for a long time, and strongly acidic electrolytic water which has a sterilizing effect and is used in a hospital.  <P>SOLUTION: An electrolytic water generator having a metal cylindrical electrode having corrosion resistant properties carrying a conductive catalytic coating, and a cylindrical diaphragm covering the outside of the cylindrical electrode is used to generate the strongly alkaline electrolytic water without contamination of NaCl for the purpose of washing, and the strongly acidic electrolytic water for the purpose of sterilization. These kinds of electrolytic water are used for the purposes respectively. Sodium metasilicate or sodium carbonate is added to the strongly alkaline electrolytic water as a buffering agent, which can maintain the detergency for a long time. The strongly acidic electrolytic water having the sterilizing effect can be obtained as high-purity electrolytic water, which can be kept at the pH3 or lower, and maintain the sterilizing effect for a long time.  <P>COPYRIGHT: (C)2006,JPO&NCIPI
The intervention group will be given cyclosporin A plus thrombopoietin (TPO) mimetic starting with 50 mg orally daily that would be increased or decreased according to response, for 3-months. Patients will be kept on weekly follow up visits and assessed by peripheral hemogram .
The invention provides application of tiamulin in preparation of a chlamydia abortus inhibitor and a tiamulin-containing chlamydia abortus inhibitor, belonging to the technical field of anti-chlamydia medicaments. The application of tiamulin with a structure shown in formula I in preparing an abortion chlamydia inhibitor or a medicament for inhibiting abortion chlamydia. On the level of animal cells and chick embryos, tiamulin effectively inhibits the proliferation of Chlamydia abortus. The tiamulin has the inhibiting effect on the Chlamydia abortus, and provides a new idea for treating the animal Chlamydia abortus disease. Because the tiamulin and the tetracycline have strong biological functions of inhibiting the chlamydia abortus, the invention also provides a pharmaceutical composition containing the tiamulin and the tetracycline, which is used for inhibiting the growth of the chlamydia abortus. The application of the pharmaceutical composition in preparing the medicine for preventing abortion of human, poultry and livestock widens the product variety for inhibiting the abortion chlamydia in the market, and can greatly improve the competitiveness of like products in the market.
NEW MATERIAL:The rhamnose homopolymer (composed of beta1 2, 2 3 bonds and having a molecular weight of about 16,000-27,000). USE:An antitumor agent. PROCESS:A bacterial strain belonging to Clostridium genus (e.g. Clostridium saccharoperbutylacetonicum ATCC 27022) is cultured in a medium containing glucose, sucrose, etc. as a carbon source. After proliferation of the bacterial strain, the medium is centrifuged at 6,000-12,000r.p.m, wased with cold water, and centrifuged again to remove the foreign materials and recover the bacterial cells. The cells are extracted wtih water, and the extract is added with a solvent such as acetone to obtain a precipitate. The precipitate is dissolved in pure water, dialyzed with pure water, concentrated under reduced pressure, freeze-dried, and treated by column chromatography, etc. to obtain the objective rhamnose homopolymer. It is administered to a man as an injection for intravenous, intra-arterial or local use, or as an oral drug such as capsule.
Amiloride HCl is usually well tolerated and, except for hyperkalemia (serum potassium levels greater than 5.5 mEq per liter — see WARNINGS), significant adverse effects have been reported infrequently. Minor adverse reactions were reported relatively frequently (about 20%) but the relationship of many of the reports to amiloride HCl is uncertain and the overall frequency was similar in hydrochlorothiazide treated groups. Nausea/anorexia, abdominal pain, flatulence, and mild skin rash have been reported and probably are related to amiloride. Other adverse experiences that have been reported with amiloride are generally those known to be associated with diuresis, or with the underlying disease being treated.

The adverse reactions for amiloride HCl listed in the following table have been arranged into two groups: (1) incidence greater than one percent; and (2) incidence one percent or less. The incidence for group (1) was determined from clinical studies conducted in the United States (837 patients treated with amiloride HCl). The adverse effects listed in group (2) include reports from the same clinical studies and voluntary reports since marketing. The probability of a causal relationship exists between amiloride HCl and these adverse reactions, some of which have been reported only rarely.
Humor can contribute to nursing practices for relieving pain and anxiety in patients with rheumatoid arthritis (RA) during intravenous (IV) biologic treatment. This study used a prospective, randomized controlled study design to investigate the effect of humor on pain and state anxiety in patients with RA receiving IV infusion therapy. Two sample groups were formed: the intervention group (watching a comedy movie) (n = 18) and the control group (usual care) (n = 18). Both groups received IV biologic therapy. A significant difference was found between the groups' pain mean scores, but the effect size was small (P < .001, η² = 0.032). The mean visual analog scale scores decreased in both groups after the treatment; however, it decreased more in the intervention group (P < .001, Md = 2.44) than in the control group (P = .017, Md = 0.83). No significant difference was found between the groups' mean state anxiety scores, and the effect size was irrelevant (P > .05, η² = 0.001). There was a significant decrease in the anxiety levels of both groups (P < .001). During IV biologic infusion therapy, watching comedy movies is recommended as a nursing care intervention for reducing pain in patients with RA in cooperation with other health professionals.
A cross-over design will be used comparing measures before and during both a mindfulness- and a positive fantasizing intervention period in individuals who remitted from two major depressive episodes (i.e. remitted Major Depressive Disorder (rMDD) patients) and a never-depressed control group. After checking for eligibility of the participants, participants will fill-out several questionnaires about their personal characteristics, experiences and expectations. These questionnaires will be used to study individual characteristics that could serve as treatment markers predicting the effectivity of interventions. Furthermore, diary measures of thought patterns (experience sampling method \[ESM\]), behavioural measures (using the Sustained Attention to Response Task \[SART\]), actigraphy, (neuro)physiological measures (impedance cardiography \[ICG\], electrocardiography \[ECG\] and electroencephalogram \[EEG\]) and measures of depressive mood (self-report questionnaires) will be performed during the week before (pre-) the interventions and the week during (peri-) performance of the interventions. In-between pre-and peri-intervention measures, there is a one month wash-out period. The order of the interventions will be counterbalanced across participants. Pre- and peri-intervention measures will be compared to study intervention effects in remitted MDD patients, remitted MDD patients vs. healthy controls and in relation with individual characteristics
The 2.0g SRT2104 treatment group will be administered eight SRT2104 capsules per day. 2.0g SRT2104 will be administered orally once daily for twenty-eight consecutive days. During non-clinic days, the subject will self-administer the test material approximately 15 minutes following consumption of a standard morning meal at home (200 cc of Ensure Plus®).
Children were individually included in the physiotherapy and rehabilitation program for 2 years, with 45 minutes each session, two days a week. All children's treatment program included targeted, personalized functional exercises according to neurodevelopmental treatment principles, and they were applied by the physiotherapists of the children in the rehabilitation centers.
###  Hypertension

Dosages must be adjusted to each patient’s needs, starting with 180 mg or 240 mg once daily. Based on the antihypertensive effect, the dose may be adjusted as needed. Individual patients, particularly ≥60 years of age, may respond to a lower dose of 120 mg. The usual dosage range studied in clinical trials was 180 mg to 480 mg once daily.

Current clinical experience with the 540 mg dose is limited; the dose may be increased to 540 mg with little or no increased risk of adverse reactions. Doses should not exceed 540 mg once daily.

While a dose of Diltiazem Hydrochloride Extended-Release Capsules, USP (Once-a-day dosage) given once daily may produce an antihypertensive effect similar to the same total daily dose given in divided doses, individual dose adjustment may be needed.
The present invention concerns fragments and variants of the HYD1 peptide; polynucleotides encoding the peptides; host cells genetically modified with the polynucleotides; vectors comprising the polynucleotides; compositions containing these peptides, polynucleotides, vectors, or host cells; and methods of using the peptides, polynucleotides, vectors, and host cells as inhibitors of aberrant cell growth in vitro or in vivo, e.g., as anti-cancer agents for treatment of cancer, such as myeloma. The present invention further includes a method of increasing the efficacy of chemotherapy and radiation therapy, comprising administering an agent that binds β1 integrin to a patient in need thereof. In one embodiment, the β1 integrin binding agent is the HYD1 peptide, or a functional fragment or variant thereof. In another aspect, the invention pertains to a composition (an adhesion trap) comprising a substrate (also referred to as a surface or support) with a HYD1 peptide, or fragment or variant thereof, immobilized to the substrate, and a method of removing circulating tumor cells (CTC) from blood by contacting a subject's blood with the immobilized peptide. Another aspect of the invention concerns a method of identifying modulators of peptide binding. Another aspect of the invention concerns a method for detecting CTC.
Dextromethorphan is an antitussive agent which, unlike the isomeric levorphanol, has no analgesic or addictive properties. The drug acts centrally and elevates the threshold for coughing. It is about equal to codeine in depressing the cough reflex. In therapeutic dosage, dextromethorphan does not inhibit ciliary activity. Dextromethorphan is rapidly absorbed from the gastrointestinal tract, metabolized by the liver and excreted primarily in the urine.

Pseudoephedrine is an α-adrenergic receptor antagonist (sympathomimetic) which produces vasoconstriction by stimulating α-receptors within the mucosa of the respiratory tract. Clinically, pseudoephedrine shrinks swollen mucous membranes, reduces tissue hyperemia, edema, and nasal congestion, and increases nasal airway patency. The vasoconstriction action of pseudoephedrine is similar to that of ephedrine. In the usual dose it has minimal vasopressor effects. Pseudoephedrine is rapidly and almost completely absorbed from the gastrointestinal tract. Acidic urine is associated with faster elimination of the drug. The drug is distributed to body tissues and fluids, including the fetal tissue, breast milk and the central nervous system (CNS).

Chlorpheniramine is an alkylamine-type antihistamine. The antihistamine in Atuss® DS Tannate Suspension acts by competing with histamine for H1 histamine receptor sites, thereby preventing the action of histamine on the cell. Clinically, chlorpheniramine suppresses the histamine-mediated symptoms of allergic rhinitis, relieving sneezing, rhinorrhea, and itching of the eyes, nose, and throat.
The OCP will be started on the first Sunday after spontaneous or induced menses. All subjects with no menses the 4 weeks before randomization will be given medroxyprogesterone acetate after a negative pregnancy test (in order to induce menses). Placebo pills will be administered to individuals randomized to OCP only in order to maintain study blinding.
The present invention relates to pharmaceutical compositions comprising Agrin fragments or derivatives thereof. In one embodiment, the Agrin fragment or derivative thereof comprises an LG3 domain of Agrin having an 8 amino acid insert at the z-position of the LG3 domain, wherein the sequence of the insert is ELANEIPV. In another embodiment, the Agrin fragment or derivative thereof further comprises the LG2 domain of Agrin. The invention also relates to hydrogels or scaffolds comprising the pharmaceutical compositions. The invention also relates to the use of a pharmaceutical composition, hydrogel or scaffold in the treatment of a wound (e.g. a slow healing wound or a non-healing wound).
Huntington's disease (HD) is a progressive neurodegenerative disease characterized by neuropsychiatric disturbance, cognitive impairment, and locomotor dysfunction. In the early stage (chorea) of HD, expression of dopamine D2 receptors (D2R) is reduced, whereas dopamine (DA) levels are increased. Contrary, in the late stage (bradykinesia), DA levels and the expression of D2R and dopamine D1 receptors (D1R) are reduced. 3-Nitropropionic acid (3-NPA) is a toxin that may replicate HD behavioral phenotypes and biochemical aspects. This study assessed the neurotransmitter levels, dopamine receptor gene expression, and the effect of acute exposure to quinpirole (D2R agonist) and eticlopride (D2R antagonist) in an HD model induced by 3-NPA in adult zebrafish. Quinpirole and eticlopride were acutely applied by i.p. injection in adult zebrafish after chronic treatment of 3-NPA (60 mg/kg). 3-NPA treatment caused a reduction in DA, glutamate, and serotonin levels. Quinpirole reversed the bradykinesia and memory loss induced by 3-NPA. Together, these data showed that 3-NPA acts on the dopaminergic system and causes biochemical alterations similar to late-stage HD. These data reinforce the hypothesis that DA levels are linked with locomotor and memory deficits. Thus, these findings may suggest that the use of DA agonists could be a pharmacological strategy to improve the bradykinesia and memory deficits in the late-stage HD.
PURPOSE: A cosmetic composition containing Astilbe chinensis var. davidii extract and adenosine is provided to promote collagen synthesis and to enhance integrin expression. CONSTITUTION: A cosmetic composition for anti-wrinkling contains 0.001-20.0 weight% of Astilbe chinensis var. davidii extract as an active ingredient. A cosmetic composition for improving skin elasticity contains Astilbe chinensis var. davidii extract as an active ingredient. The cosmetic composition additionally contains 0.001-5.0 weight% of adenosine. The cosmetic composition is manufactured in the form of lotion, essence, cream, pack, gel, ointment, patch, or spray.
Bloodstream infections caused by multidrug-resistant organisms such as Klebsiella pneumoniae are a significant challenge in managing hematological malignancies. This study aims to characterize the epidemiology of Klebsiella pneumoniae bloodstream infections specifically in patients with hematological malignancies, delineate the patterns of initial antibiotic therapy, assess the prevalence of resistant strains, identify risk factors for these resistant strains, and evaluate factors influencing patient outcomes. A retrospective analysis was conducted at a single center from January 2017 to December 2020, focusing on 182 patients with hematological malignancies who developed Klebsiella pneumoniae bloodstream infections. We compared the 30-day mortality rates between patients receiving appropriate and inappropriate antibiotic treatments, including the effectiveness of both single-drug and combination therapies. Kaplan-Meier survival analysis and multivariate logistic and Cox regression were used to identify factors influencing mortality risk. The 30-day all-cause mortality rate was 30.2% for all patients. The 30-day all-cause mortality rates were 77.2% and 8.8% in patients who received inappropriate initial treatment and appropriate initial treatment (p < 0.001). Inappropriate initial treatment significantly influenced mortality and was a key predictor of 30-day mortality, along with septic shock and previous intensive care unit (ICU) stays. Patients with carbapenem-resistant Klebsiella pneumoniae (CRKP) bloodstream infections exhibited more severe clinical symptoms compared to the CSKP group. The study demonstrates a significant association between empirical carbapenem administration and the escalating prevalence of CRKP and multidrug-resistant K. pneumoniae (MDR-KP) infections. Furthermore, the study identified inappropriate initial antibiotic therapy, septic shock, and ICU admission as independent risk factors for 30-day mortality.
The present invention discloses an external antimicrobial wipe which reduces the microbial load on the skin surface, preventing possible infections. Ethanol, isopropanol, and benzalkonium chloride are currently approved by the FDA as active ingredients, but actives are also defined as long-term use drugs. The present invention describes the formulation and use of a liquid compound forming an external polymeric skin layer, consisting of a given benzalkonium chloride concentration within the matrix, which rapidly reduces all bacterial (including MERS), viral types, and kills spores including clostridium difficile. The "second skin" concept is similar to the cellular function of the stratum corneum of human skin, acting as a barrier to foreign substances, which reduces any long-term flux of benzalkonium chloride into the epidermis, and reduces the symptoms of constant use. The second skin polymer application aggregates, entraps and kills bacteria. The "second skin" provides cosmetic moisturization, barrier effect, and skin softness.